Milk Antibiotic Residue Testing: Maximum Residue Limits and

Milk antibiotic residue testing detects veterinary drug residues — mainly beta-lactams, tetracyclines, sulfonamides, macrolides and aminoglycosides — in raw and processed milk. Authorities set maximum residue limits (MRLs) for each drug, and milk above these limits is rejected or recalled. A full workflow runs from sampling through screening to confirmation. This article covers principles, sample handling, ELISA and microbial inhibition screening, HPLC and LC-MS/MS confirmation, performance parameters, and MRL acceptance criteria.

Principle & mechanism

Antibiotic residue testing rests on two complementary detection principles. Immunological methods exploit the specific binding between an antibody and the target antibiotic, or its structural analogue, immobilized on a microplate or test strip. A competitive format is used because antibiotics are small molecules that cannot bind two antibodies simultaneously. Sample analyte competes with a labeled conjugate for antibody binding sites, so signal intensity is inversely proportional to analyte concentration.

Microbial inhibition assays operate on a different mechanism. A susceptible indicator organism grows in a nutrient medium seeded with the sample. Inhibitory substances stop this growth, producing a zone of growth delay or a color change. The two mechanisms differ in specificity. Immunoassays target defined drug classes, while inhibition assays respond to any antimicrobial activity and serve as a broad-spectrum gatekeeper.

Sample types and collection

Samples may be drawn from bulk cooling tanks, individual cows, tanker loads, or processed products such as pasteurized milk and milk powder. For bulk-tank and tanker sampling, agitate the contents before collection. Residues can distribute unevenly between the fat layer and aqueous phase, and agitation ensures the sample represents the entire volume.

Use clean, dry, inert containers. Residual detergent or sanitizer in collection vessels can inhibit microbial assays and generate false positives. Preserve samples by refrigeration near 4 °C and analyze promptly, ideally within 24 hours. For powder products, record reconstitution details. Chain-of-custody documentation — sample identification, volume, collection point, date and collector — must accompany each sample to the laboratory. Freeze portions only when repeated analysis is anticipated, and note freezing in the record. Some analytes, notably certain tetracyclines, may degrade during repeated freeze-thaw cycles.

Screening

by ELISA and microbial inhibition assays
Screening methods are selected for throughput and cost. They are applied to large sample numbers with rapid turnaround. Commercial ELISA kits cover major drug classes and typically return a qualitative or semi-quantitative result within one to two hours. Operationally, the analyst adds standards and samples to antibody-coated wells, incubates with the enzyme conjugate, washes, adds substrate, and reads absorbance. Results are judged against a decision concentration set at or below the relevant MRL.

Microbial inhibition assays, including plate diffusion formats and commercial ampoule tests, are the traditional mainstay of dairy intake control. A fixed volume of milk is dosed onto or into the seeded medium, incubated, and inspected visually for growth inhibition. Positive or suspect results from either technique are designated "screen-positive." They must not be reported as confirmed findings; they trigger confirmatory analysis. Laboratories should verify kit lot performance with control samples in each analytical run.

Confirmation by HPLC and LC-MS/MS

Confirmation quantifies and identifies the specific drug substance behind a screen-positive result. Sample preparation starts with protein precipitation using organic solvent, followed by centrifugation and solid-phase extraction cleanup. Beta-lactams and tetracyclines may require tailored extraction conditions to preserve analyte stability.

HPLC with ultraviolet, fluorescence or diode-array detection suits analytes present at sufficient concentration, with suitable derivatization where needed. LC-MS/MS has become the preferred confirmatory technique because it combines chromatographic separation with tandem mass spectrometric identification. Multiple reaction monitoring transitions — one quantifier and at least one qualifier ion per analyte — together with retention-time agreement establish identity beyond reasonable doubt. Quantification uses a matrix-matched calibration curve or isotope-dilution internal standards, which compensate for matrix effects common in milk. The same LC-MS/MS run can cover dozens of drug residues from multiple classes, supporting efficient surveillance.

Sensitivity, recovery and repeatability

Method performance must be validated before routine use and monitored during each batch. Sensitivity is expressed as the limit of detection and limit of quantification. For residue work, the practical benchmark is the decision limit and detection capability under the relevant EU performance scheme. These must sit below the MRL with a defined margin.

Recovery is assessed by spiking blank milk at multiple concentration levels and demonstrates extraction efficiency. Acceptable ranges commonly span 70–120 percent, depending on the analytical technique and validation guideline in force. Repeatability is checked by replicate analysis of spiked samples within one batch and expressed as relative standard deviation. Reproducibility across batches or analysts is verified periodically. Calibration verification, blank controls and fortified quality-control samples are included in every sequence. Results outside defined control limits invalidate the batch and require investigation and re-analysis.

MRL acceptance criteria and reporting

Maximum residue limits are set per pharmacologically active substance by authorities such as the Codex Alimentarius Commission, the European Union and national regulators. For milk, limits are commonly expressed in micrograms per kilogram. Typical MRLs for beta-lactams, tetracyclines and sulfonamides fall at single-digit to low double-digit levels. Exact values differ by jurisdiction and substance, so the laboratory must apply the limit current for the destination market.

Test reports state the analytical method used, the analytes covered, the quantitative result with measurement uncertainty where appropriate, and the applicable MRL. A clear conformity statement — compliant, non-compliant, or screen-positive pending confirmation — accompanies each result. For non-compliant findings, laboratories report confirmation data, identity criteria and QC evidence. Results should be reviewed and released under a documented authorization procedure, and retained records allow traceability from report back to the original sample.